WO2007072186A3 - Use of alpha-msh for treatment of fibroproliferative disorders - Google Patents

Use of alpha-msh for treatment of fibroproliferative disorders Download PDF

Info

Publication number
WO2007072186A3
WO2007072186A3 PCT/IB2006/003713 IB2006003713W WO2007072186A3 WO 2007072186 A3 WO2007072186 A3 WO 2007072186A3 IB 2006003713 W IB2006003713 W IB 2006003713W WO 2007072186 A3 WO2007072186 A3 WO 2007072186A3
Authority
WO
WIPO (PCT)
Prior art keywords
msh
treatment
alpha
fibroproliferative disorders
fibroproliferative
Prior art date
Application number
PCT/IB2006/003713
Other languages
French (fr)
Other versions
WO2007072186A2 (en
Inventor
Anna Catania
Stefano Gatti
Original Assignee
Fondazione Irccs Istituto Di Ricovero E Cura A Carattere Scientifico Di Natura Pubblica Ospedale Maggiore Policlinico, Mangiagalli E Regina Elena
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Irccs Istituto Di Ricovero E Cura A Carattere Scientifico Di Natura Pubblica Ospedale Maggiore Policlinico, Mangiagalli E Regina Elena filed Critical Fondazione Irccs Istituto Di Ricovero E Cura A Carattere Scientifico Di Natura Pubblica Ospedale Maggiore Policlinico, Mangiagalli E Regina Elena
Publication of WO2007072186A2 publication Critical patent/WO2007072186A2/en
Publication of WO2007072186A3 publication Critical patent/WO2007072186A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure describes the use of α-melanocyte stimulating hormone (α-MSH) and/or its derivatives or natural or synthetic analogs in the preparation of pharmaceutical compositions for treatment of fibroproliferative disorders including fibroproliferation caused by allergic inflammation.
PCT/IB2006/003713 2005-12-20 2006-12-20 Use of alpha-msh for treatment of?fibroproliferative disorders WO2007072186A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002426A ITMI20052426A1 (en) 2005-12-20 2005-12-20 USE OF THE STIMULATING A-MELANOCYTE HORMONE AND ITS DERIVATIVES OR SIMILAR FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROPROLIFERATIVE DISEASES
ITMI2005A002426 2005-12-20

Publications (2)

Publication Number Publication Date
WO2007072186A2 WO2007072186A2 (en) 2007-06-28
WO2007072186A3 true WO2007072186A3 (en) 2010-08-26

Family

ID=37969760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003713 WO2007072186A2 (en) 2005-12-20 2006-12-20 Use of alpha-msh for treatment of?fibroproliferative disorders

Country Status (2)

Country Link
IT (1) ITMI20052426A1 (en)
WO (1) WO2007072186A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20070999A1 (en) * 2007-05-17 2008-11-18 Fond Irccs Istituto Di Ricove SYNTHETIC PEPTIDE EQUIPPED WITH ANTI-INFLAMMATORY AND ANTI-MICROBIAL PROPERTIES
AU2008297551A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a defensin peptide as a therapeutic agent

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BÖHM ET AL: "Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 6959 - 6966, XP002337112 *
BÖHM ET AL: "Detection of functional melanocortin receptors in human basophils: Implications for an immunoregulatory role of alpha-MSH in allergic diseases", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 125(Suppl.1), September 2005 (2005-09-01), pages A52, XP002432908 *
BÖHM ET AL: "Melanocortins in fibroblast biology - current update and future perspective for dermatology", EXPERIMENTAL DERMATOLOGY, vol. 13(Suppl.4), 2004, pages 16 - 21, XP002432905 *
GATTI ET AL: "Inhibitory effects of the peptide (CKPV)2 on endotoxin-induced host reactions", JOURNAL OF SURGICAL RESEARCH, vol. 131, January 2006 (2006-01-01), pages 209 - 214, XP005326654 *
HILL ET AL: "Alpha-melanocyte stimulating hormone cytoprotective biology in human dermal fibroblast cells", PEPTIDES, vol. 26, February 2005 (2005-02-01), pages 1150 - 1158, XP004931286 *
LEE ET AL: "Alpha-melanocyte-stimulating hormone gene therapy reverses carbon tetrachloride induced liver fibrosis", THE JOURNAL OF GENE MEDICINE, vol. 8, February 2006 (2006-02-01), pages 764 - 772, XP002432907 *
LEE ET AL: "The effect of alpha-melanocyte-stimulating hormone on renal tubular cell apoptosis and tubulointerstitial fibrosis in cyclosporin A nephrotoxicity", TRANSPLANTATION, vol. 78, 2004, pages 1756 - 1764, XP002432906 *
LUGER: "Role of neuropeptides in UV-mediated photoageing and immunomodulation", CLINICAL AND EXPERIMENTAL DERMATOLOGY / ONLINE, vol. 25, 2000, pages 162(1) - 162(2), XP002432950, Retrieved from the Internet <URL:http://www.blackwell-synergy.com/doi/full/10.1046/j.1365-2230.2000.0604j.x> [retrieved on 20070509] *
WANG ET AL: "Electroporative alpha-MSH gene transfer attenuates thioacetamide-induced murine hepatic fibrosis by MMP and TIMP modulation", GENE THERAPY, vol. 13, March 2006 (2006-03-01), pages 1000 - 1009, XP002432909 *

Also Published As

Publication number Publication date
WO2007072186A2 (en) 2007-06-28
ITMI20052426A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
CL2003002353A1 (en) COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
MXPA05009304A (en) Indole derivatives useful for the treatment of deseases.
TW200607506A (en) Tetrahydronaphthyridine derivatives
BRPI0607198A2 (en) composition, use of composition diseases treatment method, and pharmaceutical packaging
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
CL2007003635A1 (en) COMPOUNDS DERIVED FROM 6-AMINO-PURIN-8-ONA; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PROCESS TO PREPARE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF ALLERGIC, VIRAL OR CANCER DISEASES.
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
EP1487488A4 (en) Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
MY149492A (en) Immunoglobulins directed against nogo
IL194550A (en) Isolated antibody or fragment thereof that binds to human protein tyrosine phosphatase beta, pharmaceutical compositions containing the same and uses thereof
CL2009000697A1 (en) Compounds derived from substituted 2-heteroaryl-6-phenyl-imidazol [1,2-a] pyridines; not receptor modulators; intermediate compounds; preparation procedure; pharmaceutical composition; and use in the treatment of cancer, inflammation, neurodegenerative and psychiatric diseases, epilepsy, among others.
ATE433966T1 (en) METHYLENE DIPPERIDINE DERIVATIVES
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2007111661A3 (en) Human antibodies specific for gastrin materials and methods
EP3381445A3 (en) Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP1753445A4 (en) Treatment of ocular diseases and disorders using lantibiotic compositions
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson&#39;s disease
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2007074456A3 (en) Inhibition of cxcr4 and/or cell motility by phenylalanine, cysteine or peptides containing said aminoacids

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06831774

Country of ref document: EP

Kind code of ref document: A2